Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1,24(oh)2-22-ene-24-cyclopropyl D3
2. Calcipotriene
3. Daivonex
4. Dovonex
5. Heximar Win Care
6. Mc 903
7. Mc-903
8. Pri-2205
9. Psorcutan
10. Sorilux
1. Calcipotriene
2. Dovonex
3. Daivonex
4. Sorilux
5. 112965-21-6
6. Calciptriol
7. Psorcutan
8. Calcipotriol Hydrate
9. Mc 903
10. Calcitrene
11. Mc-903
12. Calcipotriene [usan]
13. Calcipotriol [inn]
14. Calcipotriol Anhydrous
15. Chebi:50749
16. Dovonex (tn)
17. 112828-00-9
18. Pri-2201
19. Calcipotriol (jan)
20. 143nq3779b
21. (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5s)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
22. Ncgc00167465-01
23. Calcipotriol [jan]
24. Dsstox_cid_26648
25. Dsstox_rid_81793
26. Dsstox_gsid_46648
27. Divonex
28. (22e)-(24s)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrovitamin D3 / (22e)-(24s)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrocholecalciferol / Calcipotriol
29. (5z,7e,22e)-(1s,3r,24s)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
30. Smr000466353
31. Cas-112965-21-6
32. Sr-01000762910
33. Ccris 7700
34. Unii-143nq3779b
35. Pri 2201
36. Calcipotriene (usp)
37. Bms-181161
38. Calcipotrienemc 903
39. Calcipotriene [mi]
40. Epitope Id:114242
41. Schembl2853
42. Calcipotriene [vandf]
43. Calcipotriol [mart.]
44. Mls000759467
45. Mls001424130
46. Calcipotriol [who-dd]
47. Calcipotriene [usp-rs]
48. Gtpl2778
49. Chembl1200666
50. Dtxsid0046648
51. Amy2864
52. 1s19
53. Hms2051n11
54. Hms2089j08
55. Hms3269p03
56. Hms3413d04
57. Hms3677d04
58. Hms3713k08
59. Mc903
60. Calcipotriene [orange Book]
61. Calcipotriol [ep Monograph]
62. Ex-a4430
63. Zinc3921872
64. Tox21_112469
65. Bdbm50369964
66. Calcipotriene [usp Monograph]
67. Lmst03020106
68. S3739
69. Akos015855239
70. Tox21_112469_1
71. Ccg-100949
72. Cs-0387
73. Db02300
74. Nc00199
75. Stf-115469
76. Ncgc00167465-02
77. (5z,7e,22e,24s)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol
78. As-56390
79. Cpd000466353
80. Hy-10001
81. D01125
82. U-0267
83. Ab00698343-05
84. 828c009
85. Q155683
86. Sr-01000762910-3
87. Sr-01000762910-4
88. (1?,3?,5z,7e,22e,24s)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol
89. (1s,3r,5z,7e,14beta,17alpha,22e,24s)-26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene-1,3,24-triol
90. (5z,7e,22e,24s)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1.alpha.,3.beta.,24-triol
91. (5z,7e,24s)-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1alpha,3beta,24-triol
92. 9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1.alpha.,3.beta.,5z,7e,22e,24s)-
93. 9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1alpha,3beta,5z,7e,22e,24s)-
Molecular Weight | 412.6 g/mol |
---|---|
Molecular Formula | C27H40O3 |
XLogP3 | 4.3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 412.29774513 g/mol |
Monoisotopic Mass | 412.29774513 g/mol |
Topological Polar Surface Area | 60.7 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 743 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 3 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Calcipotriene |
PubMed Health | Calcipotriene (On the skin) |
Drug Classes | Antipsoriatic |
Drug Label | Dovonex (calcipotriene solution) Scalp Solution, 0.005% is a colorless topical solution containing calcipotriene monohydrate, a synthetic vitamin D3 derivative, for topical dermatologic use.Chemically, calcipotriene monohydrate is (5Z,7E,22E,24S)... |
Active Ingredient | Calcipotriene |
Dosage Form | Ointment; Cream; Solution |
Route | Topical |
Strength | 0.005% |
Market Status | Prescription |
Company | Glenmark Generics; Fougera Pharms; Tolmar; G And W Labs |
2 of 6 | |
---|---|
Drug Name | Dovonex |
PubMed Health | Calcipotriene (On the skin) |
Drug Classes | Antipsoriatic |
Drug Label | Dovonex (calcipotriene solution) Scalp Solution, 0.005% is a colorless topical solution containing calcipotriene monohydrate, a synthetic vitamin D3 derivative, for topical dermatologic use.Chemically, calcipotriene monohydrate is (5Z,7E,22E,24S)... |
Active Ingredient | Calcipotriene |
Dosage Form | Cream |
Route | Topical |
Strength | 0.005% |
Market Status | Prescription |
Company | Leo Pharma As |
3 of 6 | |
---|---|
Drug Name | Sorilux |
PubMed Health | Calcipotriene (On the skin) |
Drug Classes | Antipsoriatic |
Drug Label | SORILUX Foam contains the compound calcipotriene, a synthetic vitamin D3 analog.Chemically, calcipotriene is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19), 22-tetraene-1,3,24-triol. The structural formula is represented below:Molecular... |
Active Ingredient | Calcipotriene |
Dosage Form | Aerosol, foam |
Route | Topical |
Strength | 0.005% |
Market Status | Prescription |
Company | Stiefel Labs |
4 of 6 | |
---|---|
Drug Name | Calcipotriene |
PubMed Health | Calcipotriene (On the skin) |
Drug Classes | Antipsoriatic |
Drug Label | Dovonex (calcipotriene solution) Scalp Solution, 0.005% is a colorless topical solution containing calcipotriene monohydrate, a synthetic vitamin D3 derivative, for topical dermatologic use.Chemically, calcipotriene monohydrate is (5Z,7E,22E,24S)... |
Active Ingredient | Calcipotriene |
Dosage Form | Ointment; Cream; Solution |
Route | Topical |
Strength | 0.005% |
Market Status | Prescription |
Company | Glenmark Generics; Fougera Pharms; Tolmar; G And W Labs |
5 of 6 | |
---|---|
Drug Name | Dovonex |
PubMed Health | Calcipotriene (On the skin) |
Drug Classes | Antipsoriatic |
Drug Label | Dovonex (calcipotriene solution) Scalp Solution, 0.005% is a colorless topical solution containing calcipotriene monohydrate, a synthetic vitamin D3 derivative, for topical dermatologic use.Chemically, calcipotriene monohydrate is (5Z,7E,22E,24S)... |
Active Ingredient | Calcipotriene |
Dosage Form | Cream |
Route | Topical |
Strength | 0.005% |
Market Status | Prescription |
Company | Leo Pharma As |
6 of 6 | |
---|---|
Drug Name | Sorilux |
PubMed Health | Calcipotriene (On the skin) |
Drug Classes | Antipsoriatic |
Drug Label | SORILUX Foam contains the compound calcipotriene, a synthetic vitamin D3 analog.Chemically, calcipotriene is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19), 22-tetraene-1,3,24-triol. The structural formula is represented below:Molecular... |
Active Ingredient | Calcipotriene |
Dosage Form | Aerosol, foam |
Route | Topical |
Strength | 0.005% |
Market Status | Prescription |
Company | Stiefel Labs |
For the treatment of moderate plaque psoriasis in adults.
Treatment of psoriasis
Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin.
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
D05AX52
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
D - Dermatologicals
D05 - Antipsoriatics
D05A - Antipsoriatics for topical use
D05AX - Other antipsoriatics for topical use
D05AX02 - Calcipotriol
Absorption
Clinical studies with radiolabeled ointment indicate that approximately 6% (+3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques or 5% (+2.6%, SO) when applied to normal skin.
Route of Elimination
The active form of the vitamin, 1,25-dihydroxy vitamin D3 (calcitriol), is known to be recycled via the liver and excreted in the bile. There is evidence that maternal 1,25-dihydroxy vitamin D3 (calcitriol) may enter the fetal circulation, but it is not known whether it is excreted in human milk.
Hepatic. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone. The primary metabolites are much less potent than the parent compound.
The precise mechanism of calcipotriol in remitting psoriasis is not well-understood, however, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor while being less than 1% the activity in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis and are believed to undergo modulation of gene expression with binding of calcipotriol to the VDR. This modulation is thought to affect gene products related to cell differentiation and proliferation.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Century has been an API manufacturer for over 30 years & is the partner of choice for multipurpose custom manufacturing projects.
GDUFA
DMF Review : Reviewed
Rev. Date : 2012-11-30
Pay. Date : 2012-11-13
DMF Number : 16958
Submission : 2003-11-14
Status : Active
Type : II
Certificate Number : R1-CEP 2014-016 - Rev 01
Issue Date : 2021-12-20
Type : Chemical
Substance Number : 2284
Status : Valid
Available Reg Filing : CA, ASMF |
Certificate Number : R1-CEP 2007-223 - Rev 03
Issue Date : 2022-01-04
Type : Chemical
Substance Number : 2011
Status : Valid
Available Reg Filing : CA, ASMF |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8308
Submission : 1989-11-01
Status : Inactive
Type : II
Certificate Number : R1-CEP 2005-148 - Rev 01
Issue Date : 2013-03-13
Type : Chemical
Substance Number : 2011
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8312
Submission : 1989-11-27
Status : Inactive
Type : II
Certificate Number : R1-CEP 2005-145 - Rev 01
Issue Date : 2013-04-09
Type : Chemical
Substance Number : 2284
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8714
Submission : 1990-08-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8715
Submission : 1990-08-24
Status : Inactive
Type : II
Certificate Number : R1-CEP 2014-016 - Rev 01
Status : Valid
Issue Date : 2021-12-20
Type : Chemical
Substance Number : 2284
Certificate Number : R1-CEP 2007-223 - Rev 03
Status : Valid
Issue Date : 2022-01-04
Type : Chemical
Substance Number : 2011
Certificate Number : CEP 2009-188 - Rev 05
Status : Valid
Issue Date : 2023-11-02
Type : Chemical
Substance Number : 2011
Certificate Number : R1-CEP 2016-206 - Rev 01
Status : Valid
Issue Date : 2022-11-30
Type : Chemical
Substance Number : 2284
Certificate Number : R0-CEP 2013-170 - Rev 01
Status : Expired
Issue Date : 2016-07-19
Type : Chemical
Substance Number : 2284
Certificate Number : R1-CEP 2007-243 - Rev 01
Status : Valid
Issue Date : 2018-06-29
Type : Chemical
Substance Number : 2011
Certificate Number : R1-CEP 2010-187 - Rev 00
Status : Valid
Issue Date : 2016-09-09
Type : Chemical
Substance Number : 2284
Certificate Number : R0-CEP 2016-334 - Rev 00
Status : Expired
Issue Date : 2018-12-07
Type : Chemical
Substance Number : 2011
Certificate Number : R1-CEP 2005-145 - Rev 01
Status : Valid
Issue Date : 2013-04-09
Type : Chemical
Substance Number : 2284
Certificate Number : R1-CEP 2005-148 - Rev 01
Status : Valid
Issue Date : 2013-03-13
Type : Chemical
Substance Number : 2011
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2020-07-02
Registration Number : 20200702-211-J-456
Manufacturer Name : Chongqing Huapont Shengchem ...
Manufacturer Address : No. 666 Rongjun Road, Nanjin Avenue Hechuan District, Chongqing China
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The agreement aims to commercialize Wynzora Cream, a combination of calcipotriene and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis, in Canada.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: Wynzora
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Endo Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 15, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Endo Pharm
Deal Size : Undisclosed
Deal Type : Agreement
Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada
Details : The agreement aims to commercialize Wynzora Cream, a combination of calcipotriene and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis, in Canada.
Brand Name : Wynzora
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2024
Details:
Enstilar is a combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid, indicated as topical treatment of plaque psoriasis.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: Enstilar
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LEO Pharma Submits NDA For Enstilar® For Psoriasis Treatment in China
Details : Enstilar is a combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid, indicated as topical treatment of plaque psoriasis.
Brand Name : Enstilar
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2024
Details:
MC2 gains commercialization rights for Wynzora, an approved product indicated for treating plaque psoriasis in patients 18 years and older, through a license agreement.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: Wynzora
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Hyphens Pharma
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 12, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Hyphens Pharma
Deal Size : $2.7 million
Deal Type : Licensing Agreement
Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics
Details : MC2 gains commercialization rights for Wynzora, an approved product indicated for treating plaque psoriasis in patients 18 years and older, through a license agreement.
Brand Name : Wynzora
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 12, 2024
Details:
The product is the combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. It is indicated for the topical treatment of plaque psoriasis.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: Enstilar-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The product is the combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. It is indicated for the topical treatment of plaque psoriasis.
Brand Name : Enstilar-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 23, 2023
Details:
WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in aqueous formulation.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: Wynzora
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: MC2 Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : MC2 Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethaso...
Details : WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in a...
Brand Name : Wynzora
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2022
Details:
Positive results from the Phase III study with Lipidor’s drug candidate AKP02, which is based on calcipotriol alone & in combination with betamethasone, show that AKVANO® technology works well for drugs for treatment of psoriasis.
Lead Product(s): Calcipotriol,Betamethasone
Therapeutic Area: Dermatology Brand Name: AKP02
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Positive results from the Phase III study with Lipidor’s drug candidate AKP02, which is based on calcipotriol alone & in combination with betamethasone, show that AKVANO® technology works well for drugs for treatment of psoriasis.
Brand Name : AKP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 20, 2022
Details:
Under the terms of this agreement, RELIFE S.r.l shall register, promote, distribute and market Lipidor's calcipotriol based drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries.
Lead Product(s): Calcipotriol,Beclomethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: AKP01
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Menarini
Deal Size: $83.1 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 01, 2021
Lead Product(s) : Calcipotriol,Beclomethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Menarini
Deal Size : $83.1 million
Deal Type : Licensing Agreement
Details : Under the terms of this agreement, RELIFE S.r.l shall register, promote, distribute and market Lipidor's calcipotriol based drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries.
Brand Name : AKP01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 01, 2021
Details:
AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor’s patented AKVANO® technology.
Lead Product(s): Calcipotriol,Betamethasone
Therapeutic Area: Dermatology Brand Name: AKP02
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor’s patented AKVANO® technology.
Brand Name : AKP02
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2021
Details:
In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: Wynzora
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Almirall
Deal Size: Undisclosed Upfront Cash: $18.0 million
Deal Type: Collaboration February 17, 2021
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Almirall
Deal Size : Undisclosed
Deal Type : Collaboration
Almirall and MC2 Therapeutics Ink Collaboration for European Rights to Wynzora® Cream for Plaque ...
Details : In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
Brand Name : Wynzora
Molecule Type : Small molecule
Upfront Cash : $18.0 million
February 17, 2021
Details:
U.S. Prescribing Information (USPI) updated to include PSO-LONG clinical trial data concerning long-term use (52 weeks) of twice-weekly topical treatment with Enstilar® (calcipotriene and betamethasone dipropionate) Foam in adults with plaque psoriasis.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: Enstilar
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LEO Pharma Announces U.S. FDA Approval for Enstilar® (Calcipotriene and Betamethasone Dipropionat...
Details : U.S. Prescribing Information (USPI) updated to include PSO-LONG clinical trial data concerning long-term use (52 weeks) of twice-weekly topical treatment with Enstilar® (calcipotriene and betamethasone dipropionate) Foam in adults with plaque psoriasis.
Brand Name : Enstilar
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 22, 2020
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Calcipotriene manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Calcipotriene, including repackagers and relabelers. The FDA regulates Calcipotriene manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Calcipotriene API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Calcipotriene manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Calcipotriene supplier is an individual or a company that provides Calcipotriene active pharmaceutical ingredient (API) or Calcipotriene finished formulations upon request. The Calcipotriene suppliers may include Calcipotriene API manufacturers, exporters, distributors and traders.
click here to find a list of Calcipotriene suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Calcipotriene DMF (Drug Master File) is a document detailing the whole manufacturing process of Calcipotriene active pharmaceutical ingredient (API) in detail. Different forms of Calcipotriene DMFs exist exist since differing nations have different regulations, such as Calcipotriene USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Calcipotriene DMF submitted to regulatory agencies in the US is known as a USDMF. Calcipotriene USDMF includes data on Calcipotriene's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Calcipotriene USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Calcipotriene suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Calcipotriene Drug Master File in Korea (Calcipotriene KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Calcipotriene. The MFDS reviews the Calcipotriene KDMF as part of the drug registration process and uses the information provided in the Calcipotriene KDMF to evaluate the safety and efficacy of the drug.
After submitting a Calcipotriene KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Calcipotriene API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Calcipotriene suppliers with KDMF on PharmaCompass.
A Calcipotriene CEP of the European Pharmacopoeia monograph is often referred to as a Calcipotriene Certificate of Suitability (COS). The purpose of a Calcipotriene CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Calcipotriene EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Calcipotriene to their clients by showing that a Calcipotriene CEP has been issued for it. The manufacturer submits a Calcipotriene CEP (COS) as part of the market authorization procedure, and it takes on the role of a Calcipotriene CEP holder for the record. Additionally, the data presented in the Calcipotriene CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Calcipotriene DMF.
A Calcipotriene CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Calcipotriene CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Calcipotriene suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Calcipotriene as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Calcipotriene API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Calcipotriene as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Calcipotriene and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Calcipotriene NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Calcipotriene suppliers with NDC on PharmaCompass.
Calcipotriene Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Calcipotriene GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Calcipotriene GMP manufacturer or Calcipotriene GMP API supplier for your needs.
A Calcipotriene CoA (Certificate of Analysis) is a formal document that attests to Calcipotriene's compliance with Calcipotriene specifications and serves as a tool for batch-level quality control.
Calcipotriene CoA mostly includes findings from lab analyses of a specific batch. For each Calcipotriene CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Calcipotriene may be tested according to a variety of international standards, such as European Pharmacopoeia (Calcipotriene EP), Calcipotriene JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Calcipotriene USP).
LOOKING FOR A SUPPLIER?